Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B

Virology Journal

Volumn 10, Issue , 2013, Pages

  Li, Lei ^a,b   Shen, Hong ^a   Li, Anyi ^a   Zhang, Zhenhua ^a   Wang, Baoju ^a   Wang, Junzhong ^a   Zheng, Xin ^a   Wu, Jun ^a   Yang, Dongliang ^a   Lu, Mengji ^d   Song, Jingjiao ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antiviral research; HBV genotype B; HBV mouse model; HBx gene silencing; Hydrodynamic injection

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B(E) ANTIGEN; PLASMID VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; GENE EXPRESSION; GENE SILENCING; GENOTYPE; HEPATITIS B VIRUS; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; VIRUS GENE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

HEPATITIS B VIRUS; MUS;

EID: 84879430679     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-214     Document Type: Article

References (64)

1. Viral hepatitis B. Lai CL, Ratziu V, Yuen MF, Poynard T, Lancet 2003 362 2089 2094 10.1016/S0140-6736(03)15108-2 14697813
2. Hepatitis B virus infection-natural history and clinical consequences. Ganem D, Prince AM, N Engl J Med 2004 350 1118 1129 10.1056/NEJMra031087 15014185
3. Hepatitis B virus infection. Liaw YF, Chu CM, Lancet 2009 373 582 592 10.1016/S0140-6736(09)60207-5 19217993
4. Molecular epidemiology of hepatitis B virus. Kao JH, Korean J Intern Med 2011 26 255 261 10.3904/kjim.2011.26.3.255 22016585
5. High level hepatitis B virus replication in transgenic mice. Guidotti LG, Matzke B, Schaller H, Chisari FV, J Virol 1995 69 6158 6169 7666518
6. Expression and replication of hepatitis B virus genome in transgenic mice. Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, et al. Proc Natl Acad Sci USA 1989 186 207 211
7. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, et al. Science 1990 248 361 364 10.1126/science.1691527 1691527
8. Hepatitis B virus transgenic mouse model of chronic liver disease. Larkin J, Clayton M, Sun B, Perchonock CE, Morgan JL, et al. Nat Med 1999 5 907 912 10.1038/11347 10426314
9. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Böcher WO, Marcus H, Shakarchy R, Dekel B, Shouval D, et al. Immunology 1999 96 634 641 10.1046/j.1365-2567.1999.00704.x 10233752
10. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, et al. Hepatology 1999 29 553 562 10.1002/hep.510290228 9918935
11. Repopulation of the mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Dandri M, Burda MR, Török E, Pollok JM, Iwanska A, et al. Hepatology 2001 33 981 988 10.1053/jhep.2001.23314 11283864
12. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Huang LR, Wu HL, Chen PJ, Chen DS, Proc Natl Acad Sci USA 2006 103 17862 17867 10.1073/pnas.0608578103 17095599
13. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. Takehara T, Suzuki T, Ohkawa K, Hosui A, Jinushi M, et al. J Hepat 2006 44 267 274 10.1016/j.jhep.2005.07.030
14. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD, J Virol 2010 84 7513 7522 10.1128/JVI.00200-10 20504927
15. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Lin YJ, Huang LR, Yang HC, Tzeng HT, Hsu PN, et al. Proc Natl Acad Sci USA 2010 107 9340 9345 10.1073/pnas.1004762107 20439715
16. Immune effectors required for hepatitis B virus clearance. Yang PL, Althage A, Chung J, Maier H, Wieland S, et al. Proc Natl Acad Sci USA 2010 107 798 802 10.1073/pnas.0913498107 20080755
17. DNA Immunization with Fusion of CTLA-4 to Hepatitis B Virus (HBV) Core Protein Enhanced Th2 Type Responsesand Cleared HBV with an Accelerated Kinetic. Yin Y, Wu C, Song J, Wang J, Zhang E, et al. PLoS One 2011 6 1 11
18. Amino acid substitutions at the positions 122 and 145 of hepatitis B surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. Wu C, Deng W, Deng L, Cao L, Qin B, et al. J Virol 2012 86 4658 4669 10.1128/JVI.06353-11 22301154
19. Antiviral therapy and resistance with hepatitis B virus. Tillmann HL, World J Gastroenterol 2007 13 125 140 17206760
20. Infection Hepatitis B virus resistance to antiviral drugs: where are we going? Zoulim F, Liver Int 2011 Suppl 1 111 116
21. Inhibition of virus replication by RNA interference. Haasnoot PC, Cupac D, Berkhout B, J Biomed Sci 2003 10 607 616 14576463
22. Interfering with hepatitis C virus RNA replication. Randall G, Rice CM, Virus Res 2004 102 19 25 10.1016/j.virusres.2004.01.011 15068876
23. Inhibition of hepatitis viral replication by siRNA. Wu J, Nandamuri KM, Expert Opin Biol Ther 2004 4 1649 1659 10.1517/14712598.4.10.1649 15461576
24. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, et al. Nat Med 2005 11 944 951 16116432
25. Molecular function and biological roles of hepatitis B virus x protein. Tang H, Oishi N, Kaneko S, Murakami S, Cancer Sci 2006 97 977 983 10.1111/j.1349-7006.2006.00299.x 16984372
26. Molecular biology of the hepatitis B virus and role of the X gene. Wei Y, Neuveut C, Tiollais P, Buendia MA, Pathol Biol 2010 58 267 272 10.1016/j.patbio.2010.03.005 20483545
27. The enigmatic X gene of hepatitis B virus. Bouchard MJ, Schneider RJ, J Virol 2004 78 12725 12734 10.1128/JVI.78.23.12725-12734.2004 15542625
28. Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression. Meng Z, Qiu S, Zhang X, Wu J, Schreiter T, et al. Virology 2009 384 88 96 10.1016/j.virol.2008.11. 012 19064272
29. HBV genotype and clinical outcome of chronic hepatitis B facts and puzzles. Tseng TC, Kao JH, Gastroenterology 2008 134 1272 1273 10.1053/j.gastro.2007.12.046 18395116
30. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Kao JH, Chen PJ, Lai MY, Chen DS, Gastroenterology 2000 118 554 559 10.1016/S0016-5085(00)70261-7 10702206
31. Hepatitis B virus (HBV) genotypes/subgenotypes in china: mutations in core promoter and precore/core and their clinical implications. Yuan J, Zhou B, Tanaka Y, Kurbanov F, Orito E, et al. J Clin Virol 2007 39 87 93 10.1016/j.jcv.2007.03.005 17451999
32. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Durantel D, Carrouée-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, et al. Hepatology 2004 40 855 864 15382118
33. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Yang H, Westland C, Xiong S, Delaney WE, Antiviral Res 2004 61 27 36 10.1016/j.antiviral.2003.07.003 14670591
34. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. Lu M, Isogawa M, Xu Y, Hilken G, J Virol 2005 79 6368 6376 10.1128/JVI.79.10.6368-6376.2005 15858020
35. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, et al. Transfusion 2004 44 1332 1339 10.1111/j.1537-2995.2004.04055.x 15318857
36. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Manesis EK, Hadziyannis E, Angelopoulou OP, Hadziyannis SJ, Antivir Ther 2007 12 73 82 17503750
37. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, et al. Antivir Ther 2008 13 547 554 18672533
38. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in acohort chronically infected with hepatitis B virus. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, et al. Hepatology 2010 51 1531 1537 10.1002/hep.23464 20087968
39. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Chen CC, Ko TM, Ma HI, Wu HL, Xiao X, et al. Gene Ther 2007 14 11 19 10.1038/sj.gt. 3302846 16929350
40. A retrovirus-based system to stably silence GDF-8 expression and enhance myogenic differentiation in human rhabdomyosarcoma cells. Yang Z, Zhang J, Cong H, J Gene Med 2008 10 825 833 10.1002/jgm.1216 18563849
41. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. Sebestyen MG, Budker VG, Budker T, Subbotin VM, Zhang G, Monahan SD, et al. J Gene Med 2006 8 852 873 10.1002/jgm.921 16724360
42. Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles. Crespo A, Peydro A, Dasi F, Benet M, Calvete JJ, Revert F, et al. Gene Ther 2005 12 927 935 10.1038/sj.gt.3302469 15729372
43. M echanism of liver gene transfer by mechanical massage. Liu F, Lei J, Vollmer R, Huang L, Mol Ther 2004 9 452 457 10.1016/j.ymthe.2003.12.003 15006613
44. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. Kobayashi N, Nishikawa M, Hirata K, Takakura Y, J Gene Med 2004 6 584 592 10.1002/jgm.541 15133769
45. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Zamore PD, Tuschl T, Sharp PA, Cell 2000 101 25 33 10.1016/S0092-8674(00)80620-0 10778853
46. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Baer M, Nilsen TW, Costigan C, Altman S, Nucleic Acids Res 1990 18 97 103 10.1093/nar/18.1.97 2308839
47. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. Brummelkamp TR, Bernards R, Agami R, Science 2002 296 550 553 10.1126/science.1068999 11910072
48. HBV induced carcinogenesis. Cougot D, Neuveut C, Buendia MA, J Clin Virol 2005 34 suppl 1 75 S78 16461244
49. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. Hung L, Kumar V, FEBS Lett 2004 560 210 214 10.1016/S0014-5793(04)00113-9 14988024
50. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Han Q, Zhang C, Zhang J, Tian Z, Hepatology 2011 54 1179 1189 10.1002/hep.24505 21721030
51. Rational siRNA design for RNA interference. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Nat Biotechnol 2004 22 326 330 10.1038/nbt936 14758366
52. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, et al. Hepatology 2005 41 1349 1356 10.1002/hep.20702 15880588
53. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, et al. Nat Biotechnol 2005 23 1002 1007 10.1038/nbt1122 16041363
54. EsiRNAs inhibit hepatitis B virus replication in mice model more efficiently than synthesized siRNAs. Xuan B, Qian Z, Hong J, Huang W, Virus Res 2006 118 150 155 10.1016/j.virusres.2005.12.005 16423421
55. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. Aigner A, J Biotechnol 2006 124 12 25 10.1016/j.jbiotec.2005.12.003 16413079
56. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, et al. Mol Ther 2007 15 1145 1152 17440441
57. Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. Garcia T, Li J, Sureau C, Ito K, Qin Y, Wands J, Tong S, J Virol 2009 83 11152 11165 10.1128/JVI.00905-09 19706705
58. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP, REDS Study Group, Transfusion 2004 44 1332 1339 10.1111/j.1537-2995.2004.04055.x 15318857
59. A substitution at the amino acid position 122 of hepatitis B surface antigen (HBsAg) strongly impairs the antigenicity of HBsAg. Tian YJ, Xu Y, Zhang ZH, Meng ZJ, Tan L, et al. J Clin Microbiol 2007 45 2971 2978 10.1128/JCM.00508-07 17609325
60. Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia. Mendy ME, Kaye S, van der Sande M, Rayco-Solon P, Waight PA, et al. Virology 2006 3 23 10.1186/1743-422X-3-23
61. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, et al. J Virol 2008 82 2598 2603 10.1128/JVI.01613-07 18160442
62. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. Meng Z, Xu Y, Wu J, Tian Y, Kemper T, et al. J Virol Methods 2008 150 27 33 10.1016/j.jviromet.2008.02.008 18378325
63. Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. von Freyend MJ, Untergasser A, Arzberger S, Oberwinkler H, Drebber U, et al. J Viral Hepat 2011 18 216 226 10.1111/j.1365-2893.2010.01302.x 20367794
64. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, et al. Hepatology 2011 53 1476 1485 10.1002/hep.24195 21520166